Carcinoma in situ of urinary bladder

Also known as: Carcinoma in Situ of Bladder / Bladder cancer in situ / Carcinoma in situ of the urinary bladder / In situ Bladder Cancer / Carcinoma in situ of the bladder / Carcinoma in situ of bladder NOS / Carcinoma in situ of bladder (disorder) / Malignant neoplasm of bladder stage 0, with cancer in situ / Bladder cancer stage 0, with cancer in situ

DrugDrug NameDrug Description
DB12768BCG vaccineA vaccine indicated in the prevention of tuberculosis and the treatment of non-invasive urothelial bladder cancer.
DB10804Bacillus calmette-guerin substrain connaught live antigenIndicated for intravesical use in the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1...
DB16648Bacillus calmette-guerin substrain russian BCG-I live antigenAn intravesically-administered live BCG vaccine used to treat papillary urothelial cell carcinoma of the bladder.
DB10343Bacillus calmette-guerin substrain tice live antigenA live attenuated vaccine against Mycobacterium bovis.
DB00445EpirubicinAn anthracycline topoisomerase II inhibitor used as an adjuvant to treating axillary node metastases in patients who have undergone surgical resection of primary breast cancer.
DrugDrug NamePhaseStatusCount
DB00441Gemcitabine1Recruiting1
DB00724Imiquimod1Recruiting1
DB15632Zalifrelimab1Recruiting1
DB11714Durvalumab2Terminated1
DB00305Mitomycin3Terminated1